Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16134310 | 1.00 | MEN1 (0.70) | MEN1KMT2AADRB2ADRB1POLB | |
| SCHEMBL16134306 | 1.00 | MEN1 (0.70) | MEN1KMT2AADRB2ADRB1POLB | |
| Hydrochloric Acid SCHEMBL13737653 | 0.99 | MEN1 (0.73) | MEN1KMT2AADRB2ADRB1POLB | |
| SCHEMBL11576265 | 0.92 | PTGS1 (0.68) | MEN1KMT2AADRB2ADRB1MAPT | |
| SCHEMBL7953135 | 0.87 | PTGS1 (0.74) | MEN1KMT2AADRB2ADRB1MAPT | |
| SCHEMBL10793188 | 0.86 | ADRB1 (0.68) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL13589887 | 0.86 | ADRB2 (0.75) | MEN1KMT2AADRB2ADRB1POLB | |
| Hydrochloric Acid SCHEMBL10796153 | 0.85 | ADRB1 (0.67) | MEN1KMT2AADRB2ADRB1MAPT | |
| SCHEMBL9452451 | 0.81 | MAPT (0.66) | MEN1KMT2AADRB2ADRB1MAPT | |
| SCHEMBL8665957 | 0.80 | MAPT (0.64) | MEN1KMT2AADRB2ADRB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849863-B2 | Compounds for treating cancer, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20140296242-A1 | COMPOUNDS FOR TREATING CANCER, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296242-A1 | COMPOUNDS FOR TREATING CANCER, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2012149266-A1 | COMPOUNDS FOR TREATING CANCER, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296242-A1 | COMPOUNDS FOR TREATING CANCER, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | VHL, XPOT, XPO5 | MEN1 43/4885KMT2A 792/4885ADRB2 3272/4885 |
| US-10849863-B2 | Compounds for treating cancer, for administering, and for pharmaceutical compositions | VHL, XPOT, XPO5 | MEN1 43/4885KMT2A 792/4885ADRB2 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.